NTCP modelling – re-irradiation challenges

Alexandru Dasu
The Skandion Clinic
Uppsala, Sweden
Clinical challenge

• A patient who received previous radiation treatment comes with a second primary tumour in or near the previously treated area or a recurrence in the previously treated area.

• Options:
  – Surgery (not all patients are operable or their tumours can be resected)
  – Chemotherapy (generally a palliative approach)
  – Re-irradiation (could offer disease control)

• Challenge: Find the dose (distributions) that would allow the control of the second tumour while avoiding significant acute and late morbidity.
  – Use the tool of modelling the complication probabilities in the normal tissues taking into account both treatments.
Modelling

• To simulate a process, a concept or the operation of a system (commonly with the aid of a computer).
  – Starting from ground principles and processes (mechanistic modelling)
  – Starting from observations (empirical modelling)
  – Combining observations and principles (semi-empirical/semi-mechanistic modelling)

• The aims of modelling the process leading to complications could be:
  – To describe it
  – To predict its outcome
Modelling

• To simulate a process, a concept or the operation of a system (commonly with the aid of a computer).
  – Starting from ground principles and processes (mechanistic modelling)
  – Starting from observations (empirical modelling)
  – Combining observations and principles (semi-empirical/semi-mechanistic modelling)

• The aims of modelling the process leading to complications could be:
  – To describe it
  – To predict its outcome
**NTCP models**

- **Lyman-Kutcher-Burman (LKB) model:**
  \[
  NTCP = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{t} e^{-\frac{x^2}{2}} dx,
  \]
  where \( t = \frac{D - D_{50}}{mD_{50}} \)

- **Logit model:**
  \[
  NTCP = \frac{1}{1 + \left( \frac{D_{50}}{D} \right)^k}
  \]

- **Relative seriality (RS) model:**
  \[
  NTCP = \left\{ 1 - \prod_{i=1}^{M} [1 - P(D_i)^s]^{\Delta v_i} \right\}^{1/s}
  \]
  where \( P(D_i) = \exp \left[ -e^{\gamma - (D_i/D_{50})(\gamma - \ln 2)} \right] \)

---

Alexandru Dasu
NTCP models

- **Lyman-Kutcher-Burman (LKB) model:**
  \[
  NTCP = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{t} e^{-\frac{x^2}{2}} dx,
  \]
  - where \( t = \frac{D - D_{50}}{mD_{50}} \)
  
  Non-mechanistic

- **Logit model:**
  \[
  NTCP = \frac{1}{1 + \left(\frac{D_{50}}{D}\right)^k}
  \]

  Generally assume uniform irradiation

- **Relative seriality (RS) model:**
  \[
  NTCP = \left\{1 - \prod_{i=1}^{M} [1 - P(D_i)^s]^{\Delta v_i}\right\}^{1/s}
  \]
  - where \( P(D_i) = \exp\left[-e^{\gamma - (D_i/D_{50})(\gamma - \ln 2)}\right] \)

Alexandru Dasu
NTCP models

- The NTCP models have different shapes.

Mavroidis et al (2018)
Applying NTCP models

• What are the relevant OaR?
  – Model parameters: $\alpha/\beta$, $D_{50}$, m, k, s

• How are the dose distributions in an organ?
  – Could we use DVH reduction to find the equivalent uniform dose?

• In case of multiple plans, how was the dose deposited in the two treatments?
  – Do the hotspots coincide in the two plans?
Dose distributions in radiation therapy

- Normal tissue irradiation is seldom uniform.

Image courtesy of M. Lazzeroni

Alexandru Dasu
Dose volume histogram (DVH)

- Irradiation heterogeneity is quantified by the DVH.
**Dose volume histogram (DVH)**

- Irradiation heterogeneity is quantified by the DVH.
- Spatial distribution is lost.

![Graph showing Dose Volume Histogram](image)

**Volume of hotspots, but where in the organ?**
Dose volume histogram (DVH)

- Describe dose delivery with various doses per fraction.
- A conversion is needed to relate the doses to known thresholds.
EQD\textsubscript{2} (equivalent dose in 2 Gy fractions)

- Each bin (D\textsubscript{i}) in the DVH could be converted to the equivalent dose in 2 Gy per fraction, (EDQ\textsubscript{2})\textsubscript{i}.

\[
(EQD_2)_i = D_i \left(1 + \frac{d_i}{\alpha/\beta}\right) \quad \text{or} \quad (EQD_2)_i = D_i \left(1 + \frac{D_i/n}{\alpha/\beta}\right)
\]

Leung et al (2011)
gEUD (generalized Equivalent Uniform Dose)

- The DVH could be further compressed into the gEUD.
  \[ gEUD = \left[ \sum_{i=1}^{M} (EQD_2)_i^{1/a} \cdot \frac{V_i}{V} \right]^a \]

- The conversion of the DVH into gEUD removes any measure of the heterogeneity since it is a single value.
  - Two different DVH distributions could result in the same gEUD.
  - This is especially problematic for tissues with non-uniform sensitivity.

- gEUD values are used in NTCP models (logit and LKB).
Plan summation

- NTCP calculation often involves plan summation, e.g. main (elective) plan and a boost (or initial plan and re-irradiation plan).

DVH from the elective plan

+ 

DVH from the boost plan

Alexandru Dasu
Plan summation

- The DVH of the TPS plan sum has no radiobiological meaning as its bins are sums of physical doses from different fractionations.

- gEUDs are not additive.
- Summing the hotpots as the worst case scenario

Alexandru Dasu
Plan summation

- The DVH of the TPS plan sum has no radiobiological meaning as its bins are sums of physical doses from different fractionations.

- gEUDs are not additive.
- But EQD₂ are additive.

Alexandru Dasu
Back to basics!

- Do a voxelwise summation taking into account the fractionation patterns.

\[
(EQD_2)_i = D_i \left(1 + \frac{d_i}{\alpha/\beta}\right) \left(1 + \frac{2}{\alpha/\beta}\right) + D_i \left(1 + \frac{d_i}{\alpha/\beta}\right) \left(1 + \frac{2}{\alpha/\beta}\right)
\]

- One could produce an EQD$_2$VH to be further used for gEUD and NTCP calculations.

Alexandru Dasu
Plan summation

- The EQD\textsubscript{2} contributions of several relevant plans could be summed up:

\[
(EQD_2)_i = \left[ D_i \left( \frac{1 + \frac{d_i}{\alpha/\beta}}{1 + \frac{2}{\alpha/\beta}} \right) \right]_1 + \left[ D_i \left( \frac{1 + \frac{d_i}{\alpha/\beta}}{1 + \frac{2}{\alpha/\beta}} \right) \right]_2 + \left[ D_i \left( \frac{1 + \frac{d_i}{\alpha/\beta}}{1 + \frac{2}{\alpha/\beta}} \right) \right]_3 + \left[ D_i \left( \frac{1 + \frac{d_i}{\alpha/\beta}}{1 + \frac{2}{\alpha/\beta}} \right) \right]_4 + \cdots
\]
Plan summation

- Leung et al (2011) compared the maximum organ doses between the summation of the maximum dose and the maximum of the sum of EQD$_2$ for H&N treatments and found up to 4.2 Gy in differences.

- They also reported that the summation of maximum doses could lead to an overestimation of the NTCP.

- Most studies do not report fractionation-corrected cumulative doses, which could be an issue when data pooling is attempted.
Plan summation in retreatment

• EQD$_2$VH summation is recommended for accounting the effects of retreatments.

• There are however studies reporting NTCP calculations based on the summation of maximum dose or average OaR dose (e.g., Krauze et al 2017).
  – The lack of clinical data for model validation hampers the filtering out of erroneous approaches.

• Does one have to account for tissue recovery from the previous treatment for the new NTCP calculation?
  – How much time has passed since the previous treatment?
  – How do the radiation-induced changes modulate the response to re-irradiation?

Alexandru Dasu
Accounting for increased treatment time

- The effect of breaks could be accounted for with a time factor $f(T)$

\[
(EQD_2)_i = \sum_j \left[ D_i \left( 1 + \frac{d_i}{\alpha/\beta} \right) \right] - f(T)
\]
Time factors in radiation therapy

• This approach is used in isoeffect modelling, and could handle treatment breaks taking several weeks:

\[ f(T) = \frac{\ln_2(T-T_k)}{\frac{\alpha}{T_p} + \frac{\alpha}{\beta}} \]

• For early reacting tissues (\(\alpha/\beta>10\) Gy), \(f(T) = 0\)
  • But is it?

• For late reacting tissues (\(\alpha/\beta<3\) Gy), \(f(T) = 0\)
Time factors in radiation therapy

• This approach is used in isoeffect modelling, and could handle treatment breaks taking several weeks:

\[ f(T) = \frac{\ln_2(T-T_k)}{\alpha \frac{T_p}{T}} - \frac{\alpha/\beta}{1+\frac{2}{\alpha/\beta}} \]

• For early reacting tissues (\(\alpha/\beta>10\) Gy):

• For late reacting tissues (\(\alpha/\beta<3\) Gy):
  • Thames et al (2010) reported the existence of a time factor for prostate tumours (\(\alpha/\beta=1.5\) Gy), hence \(f(T) = \frac{\ln_2(T-T_k)}{\alpha \frac{T_p}{T}} - \frac{\alpha/\beta}{1+\frac{2}{\alpha/\beta}}\) for late reacting tissues as well.
  • The effects of the time factor might be obscured by most primary treatments being ready before the relevant \(T_k\).

Alexandru Dasu
Time factors in radiation therapy

• Which leads to an interesting development for NTCP modelling.

\[
(EQD_2)_i = \sum_j D_i \left(1 + \frac{d_i}{\alpha/\beta}\right) - \frac{\ln2 (T - T_k)}{\alpha \frac{T_p}{T_k}} \left(1 + \frac{2}{\alpha/\beta}\right)
\]

• Most treatments are shorter than \(T_k\).
  – At present we do not have (late reacting) tissue-specific recovery parameters.

• Not yet clear whether time factors are applicable at voxel level.
Time factors for re-irradiation

• Can this approach account for all long-time recovery processes?

• Acute reacting tissues usually recover completely after conventional fractionation.
  • Do SBRT treatments activate mechanisms not accounted for by the BED formalism?
  • Does one need to account for voxel-specific recovery?

• Some late reacting tissues (CNS, lung) recover partially after conventional fractionation, while others (heart, kidney) do not.
  • Can this observation be related to the other mechanisms and patterns of recovery from the first treatment course?
Data on recovery after spinal irradiation

- Spinal irradiation in rhesus monkeys.

![Graph showing proportion with myelopathy vs dose (Gy)]

Ang et al (2001)
Accounting for tissue recovery at reirradiation

- Woodley et al (2018) defined a recovery function to predict radiation myelopathy after repeated irradiation.
- Start by determining the $BED_{NTCP}$ for a clinically acceptable NTCP, e.g. 1%.
- Assuming that $BED_1$ and $BED_2$ are the BEDs for the initial and second treatments, respectively, normalised to the $BED_{NTCP}$.

$$
BED_2 = 100 \left( 1 - \frac{BED_1}{100} \right) \left[ 1 + \left( \left( 1 - \frac{BED_1}{100} \right)^{-\frac{r(t)}{r(t)+1}} - 1 \right) f(BED_1, r(t)) \right]
$$

- where

$$
f(BED_1, r(t)) = \frac{1}{2} \left[ 1 + \tanh \left( s_0 \left( BED_1 - \frac{\overline{BED}}{1 + s_1 \cdot r(t)} \right) \right) \right]
$$
More reirradiation-specific questions

• If the first treatment course induces genetic instability, can we continue using the same parameters for the BED formalism for the re-treatment course?

• In case of heterogeneous irradiations, should tolerance/NTCP calculations be performed at voxel level or rather at TRU level?

• Can we use imaging for voxel-specific quantification of normal tissue function and/or recovery parameters?
  • This leads to the possibility of having voxel-specific recovery parameters.
Patient anatomy changes

- Within one course or between the initial and retreatment courses.

- Voxel tracking through deformable image registration (DIR) is needed.
  - The DIR algorithm used could introduce a dose uncertainty in the DVH.

- Also relevant for intra-treatment changes (e.g., physiological motion).

Alexandru Dasu
Plan availability and calculation algorithms

• Candidates for re-irradiation may have received the initial plan more than a decade before.

• Is the original plan still available or it has to be reconstructed?
  – Is the CT data set still available?
  – Is the treatment machine still available in the TPS?

• What dose calculation has been used?
  – The accuracy of dose calculation varies between algorithms, with older convolution algorithms being less accurate than newer ones (AAA, CC or MC), especially in heterogeneous media.
What if different radiation modalities are used?

- Particle therapy (a potential candidate for re-irradiation) is characterised by depth and tissue-dependent RBE.
- These variations could be reflected upon the dose distributions (DVHs) used for NTCP calculations.

Alexandru Dasu

Ödén et al (2017)
RBE-dependent treatment optimisation

- Accounting for RBE variations for plan evaluation and optimisation is advancing fast.

Alexandru Dasu
Conclusions

• Available NTCP models are derived from uniform irradiations.
  – The impact of DVH reduction techniques for tissues with non-uniform sensitivity is not yet explored.

• Plan summation and voxel-tracking techniques are needed to account for real dose distributions in normal tissues.

• Treatment optimisation for particle therapy should account for RBE variations.

• Accounting for tissue recovery between treatment courses is still the most challenging aspect of re-irradiation.
Thank you!